<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01809093</url>
  </required_header>
  <id_info>
    <org_study_id>09-954</org_study_id>
    <secondary_id>IRB# 09-954</secondary_id>
    <nct_id>NCT01809093</nct_id>
  </id_info>
  <brief_title>Thrombospondin-1 and Pigmented Epithelium Derived Factor Levels in Patients With Diabetes Mellitus.</brief_title>
  <acronym>PEDF</acronym>
  <official_title>Modulation of Thrombospondin-1 and Pigment Epithelium Derived Factor Levels in Vitreous Fluid and Plasma of Patients With Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MidAtlantic Retina</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wills Eye</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      You are being asked to be in a research study to determine blood levels and vitreous levels
      of compounds called thrombospondin 1 (TSP1) and pigment epithelium derived factor (PEDF).
      These compounds exists naturally in your body.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The hypothesis tested here is that diabetic patients that express the higher molecular weight
      pigment epithelium-derived factor (PEDF) isoform have lower thrombospondin-1 (TSP1) level
      and, as a result, are at a greater risk for the development of more severe diabetic
      retinopathy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Level of thrombospondin (TSP1) and pigment epithelium derived factor (PEDF) in the vitreous and plasma</measure>
    <time_frame>up to 6 months</time_frame>
    <description>Your voluntary participation in this study may help determine how different TSP1 and PEDF levels correlate with diabetic eye disease.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">90</enrollment>
  <condition>Diabetes</condition>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Blood draw</arm_group_label>
    <description>Blood (approximately equal to 3 to 4 tablespoons) will be drawn at the Wills Eye Institute, 1 time.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Blood draw</intervention_name>
    <description>3-4 tablespoons of blood will be drawn, one time.</description>
    <arm_group_label>Blood draw</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      The level of TSP1 and PEDF in the vitreous and plasma.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with diabetes mellitus who are undergoing pars plana vitrectomy for any reason
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ability to provide written informed consent and comply with study assessments for the
             full duration of the study

          -  Diabetes Mellitus

          -  Undergoing pars plana vitrectomy for any reason

        Exclusion Criteria:

          -  Use of any anti-VEGF (vascular endothelial growth factor ) medications
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marc Spirn, M.D.</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <location>
    <facility>
      <name>Mid Atlantic Retina- Wills Eye Institute</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 7, 2013</study_first_submitted>
  <study_first_submitted_qc>March 7, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 12, 2013</study_first_posted>
  <last_update_submitted>February 17, 2017</last_update_submitted>
  <last_update_submitted_qc>February 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Wills Eye</investigator_affiliation>
    <investigator_full_name>MidAtlantic Retina</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>PEDF</keyword>
  <keyword>TSP1</keyword>
  <keyword>Thrombospondin</keyword>
  <keyword>pigment epithelium derived factor</keyword>
  <keyword>Wills Eye Institute</keyword>
  <keyword>Pars plana vitrectomy</keyword>
  <keyword>Vitreous levels</keyword>
  <keyword>Mid Atlantic Retina</keyword>
  <keyword>Blood draw</keyword>
  <keyword>Blood test</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pigment epithelium-derived factor</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

